Dermata Therapeutics, Inc.: directors' dealings · United States · SEC (Form 4)

About Dermata Therapeutics, Inc.

Dermata Therapeutics, Inc. is a dermatology-focused biotechnology company listed on NASDAQ in the United States, trading under the symbols DRMA and DRMAW. Headquartered in San Diego, California, the company was formed in December 2014 as a Delaware LLC, converted into a Delaware C-corporation in March 2021, and completed its IPO in August 2021. Its early strategy centered on prescription dermatology products and novel skin-delivery science built around a proprietary platform inspired by Spongilla lacustris. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001853816/000149315226012992/form10-k.htm)) Dermata’s lead historical asset was XYNGARI, also known as DMT310, which was studied clinically for moderate-to-severe acne. In March 2025, the company reported statistically significant results from its Phase 3 STAR-1 trial. Following that readout, management reassessed the commercial and regulatory economics of a traditional prescription-acne path. In September 2025, Dermata announced a strategic pivot away from a pure Rx model toward the development and distribution of science-backed OTC and B2B skincare products, aiming for a faster route to commercialization and a lower regulatory burden. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001853816/000149315226012992/form10-k.htm)) The company’s current strategy is to build a broader portfolio of differentiated skincare offerings for underserved conditions, with emphasis on OTC acne and adjacent dermatology indications. Dermata has described opportunities in acne, psoriasis, seborrheic dermatitis, and selected aesthetic applications, while also evaluating partnerships and licensing opportunities that could extend its pipeline. The investment case is therefore less about scale today and more about whether its delivery technology and product repositioning can create a viable commercial platform. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001853816/000149315226012992/form10-k.htm)) From a competitive standpoint, Dermata remains a small-cap, pre-commercial or early-commercial biotech facing intense competition from established dermatology and consumer-skin-care companies with stronger balance sheets, broader distribution, and more mature brands. Its potential edge lies in formulation/delivery differentiation and in the ability to leverage scientific credibility while moving products into channels that may reach consumers more quickly than a prescription-only model. The opportunity is real, but execution risk remains high. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001853816/000149315226012992/form10-k.htm)) Recent developments are important for investors. In January 2025, Dermata entered a clinical trial collaboration with Revance, later combined with Crown Laboratories, to evaluate XYNGARI with DAXXIFY in a Phase 2a study for axillary hyperhidrosis. In 2026, the company also saw multiple Form 4 insider transaction filings, keeping governance and ownership changes on the radar. Its latest SEC filings continue to emphasize losses, limited cash resources, and going-concern risk, which are central considerations for any investor following a NASDAQ-listed United States biotech of this size. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1853816/000165495425002886/drma_ex991.htm))